Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia
TA Lawrie, A Nordin, M Chakrabarti… - Cochrane Database …, 2016 - cochranelibrary.com
Background Usual‐type vulval intraepithelial neoplasia (uVIN) is a pre‐cancerous condition
of the vulval skin. Also known as high‐grade VIN, VIN 2/3 or high‐grade vulval squamous …
of the vulval skin. Also known as high‐grade VIN, VIN 2/3 or high‐grade vulval squamous …
Vulvar intraepithelial neoplasia: risk factors for recurrence
W Satmary, CH Holschneider, LL Brunette… - Gynecologic …, 2018 - Elsevier
Objective We studied a large population of women with high-grade vulvar intraepithelial
neoplasia (VIN) in order to identify patient and treatment-related risk factors for recurrence …
neoplasia (VIN) in order to identify patient and treatment-related risk factors for recurrence …
[HTML][HTML] Human papillomavirus vaccination: The ESGO–EFC position paper of the European society of Gynaecologic Oncology and the European Federation for …
EA Joura, M Kyrgiou, FX Bosch, V Kesic… - European Journal of …, 2019 - Elsevier
Vaccines against human papillomavirus (HPV) are available in Europe since 2006. They
have been highly effective in preventing infection and disease caused by the vaccine types …
have been highly effective in preventing infection and disease caused by the vaccine types …
Emerging human papillomavirus vaccines
B Ma, B Maraj, NP Tran, J Knoff, A Chen… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Identification of human papillomavirus (HPV) as the etiologic factor of cervical,
anogenital, and a subset of head and neck cancers has stimulated the development of …
anogenital, and a subset of head and neck cancers has stimulated the development of …
British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practice
J Morrison, P Baldwin, L Buckley, L Cogswell… - European Journal of …, 2020 - Elsevier
The purpose of this guideline is to collate evidence and propose evidence-based guidelines
for the diagnosis and management of adult patients with vulva carcinoma treated in the UK …
for the diagnosis and management of adult patients with vulva carcinoma treated in the UK …
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …
EA Joura, A Ulied, C Vandermeulen, MR Figueroa… - Vaccine, 2021 - Elsevier
Background Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status
FL Sand, SK Kjaer, K Frederiksen… - International journal of …, 2020 - Wiley Online Library
Human papillomavirus (HPV) is essential for developing cervical cancer and precancerous
lesions. Currently, three vaccines are available, which are effective as prophylaxis against …
lesions. Currently, three vaccines are available, which are effective as prophylaxis against …
Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease
A Pieralli, C Bianchi, N Auzzi, MG Fallani… - Archives of gynecology …, 2018 - Springer
Purpose To determine whether quadrivalent HPV vaccination is effective in reducing
recurrent disease in women with a previous history of HPV disease. Methods All women …
recurrent disease in women with a previous history of HPV disease. Methods All women …
[HTML][HTML] From the monovalent to the nine-valent HPV vaccine
S Pils, EA Joura - Clinical Microbiology and Infection, 2015 - Elsevier
An investigational monovalent human papillomavirus (HPV) 16 virus-like particle vaccine
has been shown to prevent persistent infection and cervical disease related to HPV 16 and …
has been shown to prevent persistent infection and cervical disease related to HPV 16 and …
Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind …
L Toft, M Storgaard, M Müller, P Sehr… - The Journal of …, 2014 - academic.oup.com
Background. We compared the immunogenicity and reactogenicity of Cervarix or Gardasil
human papillomavirus (HPV) vaccines in adults infected with the human immunodeficiency …
human papillomavirus (HPV) vaccines in adults infected with the human immunodeficiency …